Tulane Home Tulane Shield logo linking to site home page

Myelofibrosis Clinical Trials

 

M20-178
A Randomized, Open-Label, Phase 3 Study Evaluating Efficacy and Safety of Navitoclax in Combination With Ruxolitinib Versus Best Available Therapy in Subjects With Relapsed Refractory Myelofibrosis (TRANSFORM-2)
More Information